No single diagnosis of cerebral amyloid angiopathy automatically strips you of your license, but the condition creates a constellation of risks that frequently make driving unsafe. CAA deposits amyloid proteins in the walls of small blood vessels in the brain, weakening them and leading to microbleeds, larger hemorrhages, and progressive cognitive decline. The specific dangers for driving include sudden neurological episodes that can mimic strokes, measurable drops in executive function and processing speed, and seizures that affect roughly one in five patients. Whether you can keep driving depends on where you are in the disease, which symptoms have appeared, and how your cognitive abilities hold up on formal testing.
What CAA Does to the Brain and Why It Matters Behind the Wheel
CAA is one of the more common cerebrovascular conditions in older adults, yet it remains frequently underdiagnosed. The core problem is that amyloid beta proteins accumulate in the walls of small and medium-sized blood vessels in the brain, making them fragile and prone to leaking or rupturing. Over time this leads to cerebral microbleeds, lobar intracerebral hemorrhages, and bleeding on the brain’s surface. The cumulative effect of these injuries produces gradual motor and cognitive decline that creates significant functional limitations.1PubMed Central. Cerebral amyloid angiopathy: an underdiagnosed cause of recurrent neurological symptoms
From a driving standpoint, the concern is not just the gradual decline. CAA can produce sudden, unpredictable neurological events alongside slow erosion of the cognitive skills you need to operate a vehicle safely. That combination of chronic and acute risks makes CAA a particularly tricky diagnosis for anyone who still wants to drive.
Amyloid Spells and the Risk of Sudden Incapacitation
One of the most dangerous features of CAA for drivers is a phenomenon called “amyloid spells,” formally known as transient focal neurological episodes (TFNEs). These are brief attacks that can cause sudden numbness, paralysis on one side of the body, difficulty speaking, or visual disturbances. They typically last minutes to tens of minutes and tend to follow a stereotyped pattern, often starting in the fingers and spreading up through an arm and across one side of the body. About one in five CAA patients experiences them.2International Journal of Cerebrovascular Disease and Stroke. Amyloid Spells – Transient Focal Neurological Deficits in Cerebral Amyloid Angiopathy
The real danger is that these episodes are easily confused with transient ischemic attacks (TIAs or “mini-strokes”), but they arise from a different mechanism. Rather than being caused by a temporary blood clot blocking flow, amyloid spells are probably related to small bleeds on the brain’s surface or to cortical spreading depolarization triggered by those bleeds. The distinction matters clinically because the usual emergency treatments for a TIA, such as blood thinners, can be actively harmful in someone whose blood vessels are already fragile from CAA. More relevant for driving, these episodes may signal a very high future risk of a full symptomatic brain hemorrhage.3PubMed. Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs
Imagine losing the ability to speak or move your right arm while merging onto a highway. Even a ten-minute episode at the wrong moment could be catastrophic. If you have had even one amyloid spell, most neurologists and driving-assessment specialists will consider that a serious red flag, because the episodes tend to recur and because they signal an elevated hemorrhage risk going forward.
Executive Function, Processing Speed, and What They Mean for Driving
Even without dramatic episodes, CAA quietly erodes the cognitive skills most critical for safe driving. Research comparing CAA patients to age-matched norms has found significantly lower scores in three areas: memory, executive function, and processing speed. The deficits are steepest for executive function and processing speed, where average scores in CAA patients fell roughly one standard deviation below normal.4PubMed. Cerebral Amyloid Angiopathy Is Associated With Executive Dysfunction and Mild Cognitive Impairment
Executive function is the set of mental abilities that let you plan ahead, shift your attention between tasks, inhibit impulsive reactions, and make decisions quickly under changing conditions. Processing speed is how fast your brain takes in new information and responds. Both are non-negotiable for driving. Merging into traffic, reacting to a child darting into the street, navigating an unfamiliar route while monitoring mirrors and speed, all of these demand rapid executive processing. A driver with meaningfully impaired executive function may feel fine on a familiar, quiet road but become dangerously slow to react the moment anything unexpected happens.
The presence of microbleeds and cortical superficial siderosis, which are the MRI hallmarks of CAA, has been associated with lower cognitive test scores. One study of cognitively impaired patients found that those with these imaging features scored substantially lower on standard screening tests compared to those without them.5Stroke. Abstract TP33: Microhemorrhages and Cortical Superficial Siderosis in Cognitively Impaired Patients: Prevalence and Risk Factors That said, the picture is not perfectly straightforward. A memory-clinic study found that in more detailed statistical models, overall white matter disease severity was a stronger predictor of cognitive performance than the microbleeds or siderosis themselves.6PubMed. Cerebral Microbleeds and Superficial Siderosis: Vascular Correlates and Cognition in a Memory Clinic The practical implication is that two people with the same CAA diagnosis on imaging can have quite different levels of cognitive function, and the degree of white matter damage may be a better indicator of how impaired someone actually is day to day.
Seizure Risk and Driving Restrictions
Seizures are a well-recognized complication of CAA, and they carry their own independent implications for driving. Across studies, seizures affect roughly one in five CAA patients. One analysis found seizures in about 18% of patients,7PubMed. Prevalence and risk factors of seizures in cerebral amyloid angiopathy and another found a similar rate of about 20%, with seizures actually being the first symptom that led to the CAA diagnosis in over a third of those cases.8PubMed. Incidence and risk factors associated with seizures in cerebral amyloid angiopathy
Seizure-related driving laws vary by jurisdiction, but almost everywhere a person who has had a seizure must be seizure-free for a defined period, typically somewhere between three months and a year depending on where you live, before driving is permitted again. If your CAA has produced a seizure, that waiting period applies regardless of whether the seizure was a one-time event or part of a pattern. Given that more than a third of CAA patients with seizures had them as their initial presenting symptom, some people discover they have CAA precisely because a seizure behind the wheel or elsewhere prompted medical workup. The combination of an unpredictable seizure risk and the underlying hemorrhage risk makes the licensing conversation especially urgent for this group.
How Driving Fitness Gets Assessed
There is no single test that determines whether someone with CAA should stop driving. Instead, the evaluation typically involves a combination of cognitive screening, neuropsychological testing, and sometimes a formal on-road or simulator-based driving assessment.
Neuropsychological tests are a key piece of the puzzle, but they come with an important caveat. A study examining the predictive value of these tests found that raw cognitive scores were significantly better at predicting actual driving errors than scores that had been adjusted for age and education. The demographically adjusted scores, the kind routinely used in clinical settings, failed to reach statistical significance as predictors of driving performance.9PubMed Central. Prediction of driving ability with neuropsychological tests: demographic adjustments diminish accuracy The logic makes sense when you think about it: driving does not grade on a curve. It does not matter that your processing speed is above average “for a 78-year-old with 10 years of education” if your absolute processing speed is too slow to react to a sudden stop on the highway. What matters for safety is your raw ability, not how you compare to peers with the same background.
Off-road driving evaluations, often conducted by occupational therapists, test specific skills that map onto real driving demands. Research on comprehensive off-road testing has identified five key ability clusters that matter: higher-order visuospatial skills, basic visual recognition and responding, anticipatory braking, defensive steering, and the behavioral signs of complex attention.10American Journal of Occupational Therapy. Off-road driving evaluations for persons with cerebral injury: a factor analytic study of predriver and simulator testing These abilities capture a lot of what CAA tends to impair. If you or a family member are pushing for an objective assessment rather than relying on self-report, requesting a formal driving evaluation through an occupational therapy program is one of the most practical steps you can take. Many rehabilitation hospitals and some outpatient clinics offer these assessments.
Legal Obligations and Who Makes the Call
The question of who decides whether a person with CAA should stop driving is tangled in law, ethics, and family dynamics. Physicians routinely care for patients whose ability to drive is compromised by a physical or cognitive condition, and managing that information carries both ethical and legal weight.11PubMed Central. Reporting by physicians of impaired drivers and potentially impaired drivers
In some jurisdictions, physicians are legally required to report patients they believe are medically unfit to drive. In others, reporting is voluntary but physicians are protected from liability if they do report. The rules vary widely by state and country, and there is no universal standard. What is consistent is that the physician’s role is to assess fitness and recommend accordingly, while the licensing authority (your DMV or equivalent) makes the final legal determination. A neurologist who diagnoses CAA may recommend driving cessation, trigger a mandatory reporting process, or refer you for a formal driving assessment, depending on local regulations and the severity of your symptoms.
This is where it gets uncomfortable for families. A patient with impaired executive function may lack the insight to recognize their own limitations behind the wheel. Family members often notice problems long before the person with CAA does, things like drifting in lanes, delayed reactions at intersections, getting lost on familiar routes, or small fender-benders that start accumulating. If your neurologist has not raised the driving question, bringing it up yourself during an appointment is entirely appropriate. You can also contact your local licensing authority directly to request a medical review of someone’s driving privileges, though this can be a fraught decision within a family.
Life After Driving Cessation
Giving up driving is one of the most emotionally loaded consequences of any neurological diagnosis. It represents a loss of independence, spontaneity, and social connection. Research on patients with cognitive impairment who were advised to stop driving found that adherence to the recommendation was reasonably high, with about 79% of those told to stop actually doing so.12PubMed Central. Adherence to driving cessation advice given to patients with cognitive impairment and consequences for mobility Being female, having more advanced cognitive impairment, perceiving one’s own health as declining, and receiving a clear recommendation from a clinician all made people more likely to follow through.
The mobility consequences, however, are real. Patients who stopped driving used fewer forms of alternative transportation overall compared to those who continued driving. That said, roughly 40% of those who stopped were able to increase their use of cycling or public transit to partially compensate.12PubMed Central. Adherence to driving cessation advice given to patients with cognitive impairment and consequences for mobility These numbers suggest that while the transition is difficult, it does not have to mean total isolation. Planning for it early, before a crisis forces the issue, makes a significant difference. Setting up ride-sharing accounts, establishing routines with family or volunteer driver programs, and exploring local paratransit services can soften the blow.
One thing worth noting is that about one in five patients advised to stop driving did not comply. The reasons are predictable: they felt fine, they lived in areas with limited transit, or they simply did not accept the recommendation. For caregivers watching someone with CAA continue to drive against medical advice, the situation is deeply stressful. Having a documented physician recommendation on file, and knowing the reporting mechanisms available in your area, gives you concrete options rather than leaving you to argue about it at the dinner table.
Anti-Amyloid Therapies and a Newer Driving Concern
With the recent approval of anti-amyloid antibody therapies for Alzheimer’s disease, a new wrinkle has emerged that is directly relevant to CAA patients. These drugs can cause amyloid-related imaging abnormalities, known as ARIA, which include brain swelling (ARIA-E) and microbleeds (ARIA-H). CAA is one of the strongest risk factors for developing ARIA during treatment, which is why many trials have either excluded participants with significant CAA or monitored them especially closely.
ARIA events during clinical trials were mostly asymptomatic on imaging, but among those who did have symptoms, the rates ranged from about 6% to 39% depending on the drug and dose. The most commonly reported symptoms included headache, confusion, vomiting, and visual or gait disturbances.13PubMed Central. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics Confusion and gait disturbance are obviously relevant to driving safety. If you have CAA and are being considered for one of these therapies, or are already on one, the possibility of developing ARIA symptoms should factor into discussions about whether driving remains appropriate during treatment. Monitoring MRIs are part of the treatment protocol, and new ARIA findings, even if asymptomatic, may prompt your care team to reassess your driving status.
When the Answer Is Not Yet “Stop”
Not everyone diagnosed with CAA needs to hand over their keys immediately. The disease exists on a spectrum. Some people are diagnosed incidentally, when an MRI for another reason reveals a few scattered microbleeds and the characteristic pattern of CAA. Others are diagnosed after a major hemorrhagic stroke. The appropriate response to each scenario is vastly different.
If you have imaging findings consistent with CAA but no history of hemorrhage, no amyloid spells, no seizures, and normal or near-normal cognitive testing, your neurologist may determine that driving remains safe for now with regular monitoring. The key is “for now.” CAA is a progressive condition, and the risk of developing any of these complications increases over time. Annual or semi-annual cognitive screening, periodic MRI surveillance, and honest conversations about any new symptoms are the price of continued driving. Any new event, whether it is a spell, a bleed, a seizure, or a noticeable cognitive dip, should trigger an immediate reassessment.
Some people find it helpful to set concrete, pre-agreed benchmarks with their neurologist: “If my MoCA score drops below X, we revisit driving.” “If I have any episode of numbness or speech difficulty, I stop driving until we evaluate.” These benchmarks take the emotion out of a decision that feels deeply personal, turning it into a medical protocol rather than a family argument. They also give the person with CAA a sense of control over the process, which matters psychologically even when the disease itself feels uncontrollable.
One practical step that often gets overlooked is restricting rather than eliminating driving as an intermediate measure. Some people with mild CAA-related deficits do fine on familiar, low-complexity routes in daylight but struggle with highway driving, night driving, or navigating unfamiliar areas. A graduated restriction, limiting driving to daytime, local, low-traffic conditions, can preserve some independence while reducing risk. This is not a permanent solution, but for someone in the early stages it can buy meaningful time and quality of life while the situation is monitored.